In a rodent model of inflammatory bowel disease, treatment with Astragalus resulted in a reduction in the activity of interleukin 1 beta (IL-1β) and TNFα, key inflammatory mediators, through inhibiting NF-κB activation and ERK and JNK phosphorylation. This evidence concerns the gene IL1B and inflammatory bowel disease.